Nano Self-assembly of μ-Conotoxin CnIIIC with Enhanced Muscle Relaxation Effect

Area of Science:

• Biochemistry
• Pharmacology
• Nanotechnology

Background:

• Muscle relaxants are crucial in anesthesia, targeting voltage-gated sodium channels.
• μ-conotoxin CnIIIC is a potent inhibitor but faces challenges in clinical use due to poor stability and rapid clearance.
• This study explores molecular self-assembly to improve μ-conotoxin CnIIIC's therapeutic potential.

Purpose of the Study:

• To design and synthesize novel μ-conotoxin CnIIIC derivatives with enhanced self-assembly properties.
• To evaluate the in vivo efficacy and safety profile of these derivatives.
• To demonstrate the utility of molecular self-assembly in overcoming limitations of peptide-based drugs.

Main Methods:

• Synthesized two μ-conotoxin CnIIIC derivatives (S1-CnIIIC, S2-CnIIIC) via site-specific modification.
• Characterized self-assembly properties, including critical micelle concentration for S2-CnIIIC.
• Assessed neuromuscular blockade duration and systemic toxicity in a mouse model.

Main Results:

• S2-CnIIIC demonstrated efficient micellar structure formation (CMC: 524.8 μM), indicating superior self-assembly.
• S2-CnIIIC significantly prolonged neuromuscular blockade compared to native CnIIIC.
• S2-CnIIIC exhibited a reduced systemic toxicity profile.

Conclusions:

• Molecular self-assembly significantly improved the stability and pharmacological performance of the peptide inhibitor.
• Side-chain engineering effectively modulated supramolecular assembly for controlled drug release.
• S2-CnIIIC shows promise as a next-generation muscle relaxant with enhanced efficacy and safety.